Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. Cost Watchdog Rejects Lucentis’ Extended Use In Eye Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting

You may also be interested in...

Alimera Resubmits Iluvien In U.S. As It Begins EU Launch

The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.

Lucentis Price Concessions Win Partial Victory; NICE Clears Drug With Restrictions

Britain's cost watchdog NICE changed its mind on Lucentis, and now recommends it for treating diabetic macular edema, after Novartis offered a steeper discount – but the eye drug’s price tag remains high, so only a subgroup of British patients will receive it.

Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis

Regeneron has designed the launch strategy of its bimonthly wet AMD injection Eylea to head off any reimbursement issues.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts